Form 4: Arrowhead Pharmaceuticals Director Acquires Shares Through Restricted Stock Units

Director Adeoye Olukotun acquired 16,733 shares of Arrowhead Pharmaceuticals through restricted stock units on December 18, 2024.

Summary

• On December 18, 2024, Adeoye Olukotun, a director at Arrowhead Pharmaceuticals, acquired 16,733 shares of common stock.
• The acquisition was made through restricted stock units at a price of $22.99 per share.
• These restricted stock units will vest in one installment on the first anniversary date.
• Following this transaction, Mr. Olukotun beneficially owns 39,590 shares of Arrowhead Pharmaceuticals.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as it reflects a director's acquisition of shares, which can be seen as a sign of confidence. However, it is a routine filing and not a major event.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Form 4 filings are a standard practice for all publicly traded companies in the US, and this filing is consistent with those standards.
• The acquisition of shares through restricted stock units is a common form of compensation for directors and executives in publicly traded companies.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates

Keywords

Arrowhead Pharmaceuticals, Director, Share Acquisition, Restricted Stock Units, Insider Trading, ARWR, Equity